



Regulus Therapeutics Inc.
Investor Relations Department
10614 Science Center Dr
San Diego, CA 92121
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: RGLS

| | |
|---------------|---|
| Last Trade: | 0.91 |
| Trade Time: | 10:54 AM ET Dec 12, 2017 |
| Change: | 0.03 ↑ (+3.455%) |
| Day Range | 0.87 - 0.92 |
| 52-Week Range | 0.79 - 2.75 |
| Volume | 331,802 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Regulus maintains its corporate headquarters in La Jolla, CA.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Nov 7, 2017*
[Regulus Reports Third Quarter 2017 Financial Results and Recent Events](#)
- Oct 31, 2017*
[Regulus to Provide Third Quarter 2017 Financial Results on November 7, 2017](#)
- Aug 30, 2017*
[Regulus to Present at the 2017 Wells Fargo Healthcare Conference](#)
- Aug 8, 2017*
[Regulus to Present at the 2017 Wedbush PacGrow Healthcare Conference](#)
- Aug 1, 2017*
[Regulus Reports Second Quarter 2017 Financial Results and Recent Events](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 3, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 8, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017*
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*
[Quarterly Report \(10-Q\)](#)